Healthtech Solutions, Inc. HLTT
We take great care to ensure that the data presented and summarized in this overview for Healthtech Solutions, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in HLTT
Top Purchases
Top Sells
About HLTT
Healthtech Solutions, Inc., through its subsidiaries, operates as a life sciences company. It focuses on the development of wound care products for acute and chronic wounds, including AmnioBind, a placental membrane allograft for burns and non-healing wounds, such as diabetic foot ulcers. The company also engages in the development of ultrasound imaging and artificial intelligence-based image analysis software for the applications in treatment of chest and musculoskeletal system. In addition, it is developing software technology that compares a healthy heart rhythm electronic signal with a damaged heart's signal that derives an electronic signal representing the curative waveform. The company was founded in 2018 and is based in Tuckahoe, New York.
Insider Transactions at HLTT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 16
2022
|
James G. Wolf > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
33,700
+0.88%
|
$67,400
$2.5 P/Share
|
|
Dec 15
2022
|
James G. Wolf > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
85,100
+2.2%
|
$170,200
$2.5 P/Share
|
|
Dec 14
2022
|
James G. Wolf > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
136,200
+3.55%
|
$272,400
$2.5 P/Share
|
|
Nov 22
2022
|
Paul Elliot Mann Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,000,000
+25.0%
|
-
|
|
Nov 21
2022
|
James G. Wolf > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
24,700
+0.69%
|
$49,400
$2.5 P/Share
|
|
Nov 17
2022
|
James G. Wolf > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
300
+0.01%
|
$600
$2.5 P/Share
|
|
Nov 01
2022
|
James G. Wolf > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
8,500
+1.03%
|
$17,000
$2.15 P/Share
|
|
Oct 21
2022
|
James G. Wolf > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
14,500
+3.38%
|
$29,000
$2.15 P/Share
|
|
Jun 30
2022
|
Paul Elliot Mann Director |
BUY
Exercise of conversion of derivative security
|
Direct |
500,000
+20.0%
|
-
|
|
Nov 10
2021
|
Paul Elliot Mann Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,500,000
+50.0%
|
-
|